KLHDC2

Across TCGA pan-cancer cohorts, KLHDC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KLHDC2 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KLHDC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KLHDC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where KLHDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	IV	0.567	0.898	.027	17	view →
LSCC	OS	Median	All	0.952	0.800	.009	15	view →
LUAD	DFS	Median	All	0.630	0.856	<.001	11	view →
CCRCC	OS	Tertile	III,IV	0.860	0.565	.027	8	view →
PDAC	OS	Median	II,III,IV	0.934	0.722	.004	4	view →
GBM	DFS	Median	All	0.461	0.291	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KLHDC2–HNSC (DFS)

Open the HNSC breakdown →